Investor Relations (IR) Questions: Labstyle Innovations $DRIO
Click here to return to the biotech IRQ Index
Information as of: June 2013
COMPANY BACKGROUND:
LabStyle Innovations is developing technology with the goal of allowing consumers to utilize a smart phone as an easy and affordable laboratory testing platform. The Company's lead product in development, DARIO, is a glucometer. Features of the DARIO smart phone app include an insulin calculator, nutrition data, case history, monitoring, and a journal.
LabStyle Innovations began trading on the Over-the-Counter Bulletin Board and the OTCQB Market on April 9, 2013 under the stock ticker DRIO. The Company was incorporated in Delaware on August 11, 2011. On September 14, 2011, the Company's subsidiary, LabStyle Innovation Ltd. was incorporated in Israel.
-1- When is the last time DRIO raised cash through an offering (diluted)?
-a- The Company initiated a private placement offering on March 29, 2013 resulting in the sale of 40 units. Converting units into shares, the Company sold 4,000,000 shares at $2.50 per share raising $10,000,000. Net proceeds to the Company after expenses related to the offering were $8,985,510.
-a- The Company issued 2,000,000 warrants in connection with the offering at an exercise price of $5.00 per share and expire on April 4, 2016.
-2- How much cash (not cash equivalents) does DRIO have?
-b- On March 31, 2013, Cash & Cash Equivalents were $294,897. Subsequent to March 31, 2013, the Company raised net proceeds of approximately $8,985,510 in a private placement offering. The Company also has commitments to receive $500,000 on or before July 17, 2013 in connection to private placement offering from 2012.
-3- What and approximately when is the next known catalyst?
-c- The Company expects to obtain CE mark clearance to market Dario in Europe in the coming months.
-c- The Company anticipates the commercial launch of Dario in Europe later this year.
-d- “A U.S. 510(k) application as a Class-II medical device is also expected in the second half of 2013, which if approved, could lead to the U.S. launch in 2014.”
-4- What is DRIO's quarterly cash burn?
-e- Operating Expenses...............1Q 2013.............1Q 2012
Research & Development...........$675,414............$171,670
Marketing & pre-production... ....$497,028............$0
Genderal & Administrative.......$1,903,725............$323,076
Total operating loss..................$3,076,167............$494,746
-f- Assuming commercial sales will commence in 2013, management believes the Company has sufficient resources to continue operations until at least January 2014.
-5- Does DRIO have an existing line of credit and if so how much can they draw against it?
After reviewing the Company's public filings and press releases, I was unable to find any reference to a credit facility. I do not believe the Company has one, however, for conformation I recommend contacting the Company.
#IRQ research and IR responses are archived at http://www.biotechduediligence.com/ir-questions.html.
RESOURCES:
Company Background: DRIO website and public filings.
-a- Page 15, DRIO 10-Q for the period ending 03/31/2013
-b- Page 20, DRIO 10-Q for the period ending 03/31/2013
-c- DRIO PR 05/14/2013 http://mydario.investorroom.com/index.php?s=43&item=17
-d- @JNapodano Seeking Alpha write-up http://seekingalpha.com/article/1436791-labstyle-innovations-glucose-monitoring-for-the-mobile-age
-e- Page 3, DRIO 10-Q for the period ending 03/31/2013
-f- Page 6, DRIO 10-Q for the period ending 03/31/2013
DRIO's 10-Q for the period ending 03/31/2013 can be accessed athttp://mydario.investorroom.com/SECFilings.
Don't forget to visit http://www.biotechduediligence.com/ir-questions.html for the complete archive of #IRQ research and IR responses.
Suggested reading on DRIO:
1) @JNapodano, Jason Napodano's Seeking Alpha write-up,http://seekingalpha.com/article/1436791-labstyle-innovations-glucose-monitoring-for-the-mobile-age.
2) @Chemistfrog, Chemistfrog's write-up, http://www.benzinga.com/markets/13/05/3627905/investments-in-medical-science-fiction
COMPANY BACKGROUND:
LabStyle Innovations is developing technology with the goal of allowing consumers to utilize a smart phone as an easy and affordable laboratory testing platform. The Company's lead product in development, DARIO, is a glucometer. Features of the DARIO smart phone app include an insulin calculator, nutrition data, case history, monitoring, and a journal.
LabStyle Innovations began trading on the Over-the-Counter Bulletin Board and the OTCQB Market on April 9, 2013 under the stock ticker DRIO. The Company was incorporated in Delaware on August 11, 2011. On September 14, 2011, the Company's subsidiary, LabStyle Innovation Ltd. was incorporated in Israel.
-1- When is the last time DRIO raised cash through an offering (diluted)?
-a- The Company initiated a private placement offering on March 29, 2013 resulting in the sale of 40 units. Converting units into shares, the Company sold 4,000,000 shares at $2.50 per share raising $10,000,000. Net proceeds to the Company after expenses related to the offering were $8,985,510.
-a- The Company issued 2,000,000 warrants in connection with the offering at an exercise price of $5.00 per share and expire on April 4, 2016.
-2- How much cash (not cash equivalents) does DRIO have?
-b- On March 31, 2013, Cash & Cash Equivalents were $294,897. Subsequent to March 31, 2013, the Company raised net proceeds of approximately $8,985,510 in a private placement offering. The Company also has commitments to receive $500,000 on or before July 17, 2013 in connection to private placement offering from 2012.
-3- What and approximately when is the next known catalyst?
-c- The Company expects to obtain CE mark clearance to market Dario in Europe in the coming months.
-c- The Company anticipates the commercial launch of Dario in Europe later this year.
-d- “A U.S. 510(k) application as a Class-II medical device is also expected in the second half of 2013, which if approved, could lead to the U.S. launch in 2014.”
-4- What is DRIO's quarterly cash burn?
-e- Operating Expenses...............1Q 2013.............1Q 2012
Research & Development...........$675,414............$171,670
Marketing & pre-production... ....$497,028............$0
Genderal & Administrative.......$1,903,725............$323,076
Total operating loss..................$3,076,167............$494,746
-f- Assuming commercial sales will commence in 2013, management believes the Company has sufficient resources to continue operations until at least January 2014.
-5- Does DRIO have an existing line of credit and if so how much can they draw against it?
After reviewing the Company's public filings and press releases, I was unable to find any reference to a credit facility. I do not believe the Company has one, however, for conformation I recommend contacting the Company.
#IRQ research and IR responses are archived at http://www.biotechduediligence.com/ir-questions.html.
RESOURCES:
Company Background: DRIO website and public filings.
-a- Page 15, DRIO 10-Q for the period ending 03/31/2013
-b- Page 20, DRIO 10-Q for the period ending 03/31/2013
-c- DRIO PR 05/14/2013 http://mydario.investorroom.com/index.php?s=43&item=17
-d- @JNapodano Seeking Alpha write-up http://seekingalpha.com/article/1436791-labstyle-innovations-glucose-monitoring-for-the-mobile-age
-e- Page 3, DRIO 10-Q for the period ending 03/31/2013
-f- Page 6, DRIO 10-Q for the period ending 03/31/2013
DRIO's 10-Q for the period ending 03/31/2013 can be accessed athttp://mydario.investorroom.com/SECFilings.
Don't forget to visit http://www.biotechduediligence.com/ir-questions.html for the complete archive of #IRQ research and IR responses.
Suggested reading on DRIO:
1) @JNapodano, Jason Napodano's Seeking Alpha write-up,http://seekingalpha.com/article/1436791-labstyle-innovations-glucose-monitoring-for-the-mobile-age.
2) @Chemistfrog, Chemistfrog's write-up, http://www.benzinga.com/markets/13/05/3627905/investments-in-medical-science-fiction